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Abstract
• Background: Allergic rhinitis (AR) is a very common debilitating
disease that can be detrimental to one’s lifestyle, work, and home life.
Immunotherapy is the only treatment option that has disease modifying
capabilities with a proper therapeutic regimen. Subcutaneous
immunotherapy (SCIT) was developed over 100 years ago and has been
the gold standard in immunotherapy for many years in the United
States. During these years many adverse reactions have been reported
with SCIT along with non-adherence to total treatment. The
introduction of sublingual immunotherapy (SLIT) over 20 years ago
gave providers a promising alternative to SCIT.
• Method: A review of literature was performed to gain information on
studies comparing SLIT to SCIT for treating allergic rhinitis. This
review includes head to head clinical outcomes from systematic
reviews and meta-analyses. Efficacy, cost, adherence, and adverse
reactions was analyzed between SLIT and SCIT to determine if SLIT is
a practical treatment option.
• Results: The results indicate that treatment with SLIT is comparable to
SCIT. SLIT significantly reduces the symptoms of AR with -0.49 SMD
and SCIT with -0.73 SMD. Both SCIT and SLIT are generally safe
medications when administered properly. SCIT demonstrates a higher
risk of systemic reactions with anaphylaxis occurring 0.72% versus
0.33% in placebo. Comparative data shows that SLIT is an effective
alternative to SCIT and has equivalent to better adherence to treatment.
• Application: It is important for providers to understand the detrimental
effects of AR and treat the disease process aggressively. AR may be
commonly misdiagnosed, so understanding the disease process and how
it can mimic others will promote better treatment outcomes and patient
satisfaction. Ideally, SLIT will be seen as a viable option compared to
SCIT for treating allergic rhinitis in patients where symptomatic
treatment options do not suffice.

Introduction
• AR is a debilitating disease that affects millions of people
throughout the world. It accounts for numerous office visits thus
increasing the cost of health care for those who suffer. Many
treatments are available to manage the symptoms, but only one
kind of drug has shown success in modifying the disease.
Symptomatic medications are not curative in nature, so they
contribute to added cost over a lifetime. SCIT and SLIT are used
to modify the disease process by desensitizing the body’s
response to allergens. The purpose of this study is to determine
whether SLIT is as effective as SCIT in treating AR.

Statement of the Problem
• Insurance deductibles are constantly on the rise and a debilitating
disease like AR will make out of pocket expenses increase for
those who suffer. SCIT has been the mainstay for treating severe
AR, but it can be problematic for patients to continuously go to
the physician’s office to receive shots when they can take SLIT at
the convenience of their home. Another factor with traditional
immunotherapy is safety. More statistical information is needed to
compare SCIT and SLIT for safety and efficacy so clinicians can
decide which treatment is best for their patient.

Research Questions

Discussion

• In patients with allergic rhinitis, is sublingual immunotherapy
effective for reducing allergic rhinitis when compared to
subcutaneous immunotherapy?
• SLIT versus SCIT in safety, adherence, and cost effectiveness.

• These findings suggest that treatment with SLIT is an effective
alternative to SCIT for reducing symptoms associated with AR
and decreasing the immunologic response.
• When comparing safety of the two therapies, SLIT had less
serious adverse events when compared to SCIT. Some minor
adverse reactions and few systemic reactions were noted with
SLIT, but SCIT carries a higher risk for anaphylaxis during
treatments with fatalities being rare.

Literature Review
• Current literature was studied to evaluate all information
containing sublingual immunotherapy and subcutaneous
immunotherapy when treating allergic rhinitis in the form of
RCTs, Cochrane meta-analyses, non-Cochrane meta-analyses,
systematic literature reviews, and large pharmacy refill database
studies.

• Adherence to treatment was found to have conflicting evidence.
In many RCTs SLIT showed superiority over SCIT for adherence,
but information from large pharmacy refill databases showed that
more patients on SCIT were continuing treatment after three years
when compared to SLIT.

• Pathophysiology

• SLIT and SCIT showed to have significant cost reduction over
placebo and studies have shown that SLIT is slightly favorable
over SCIT.

– AR is a chronic disease where allergens trigger an allergic
response
– Exposure to certain extrinsic proteins can lead to specific IgE to
the protein in a Type I allergic reaction.
– Specific immunotherapy desensitizes the body’s response.
• Efficacy between SLIT and SCIT

Effectiveness of SLIT and SCIT
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– In one SLIT meta-analysis, 49 RCTs were examined totaling
4,589 patients. It showed a clinically significant reduction in
symptomatic score with -0.49 SMD (P<0.001) and medication
score with -0.32 SMD (P<0.001) (Aboshady et al. 2014).
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– Aboshady et al. 2014, found in a SCIT meta-analysis that 8%
and 7% of patients in the treated groups experienced grades II
and III systemic reactions with anaphylaxis (grade IV)
occurring in 3 cases (0.72%)
– In one SLIT meta-analysis, it was shown that it generally
produces minor local reactions of the gastrointestinal system.
Calderón et al. 2013, conducted a study that calculated the
amount of doses given for SLIT to be at one billion worldwide
from 2000 to 2010 and only found eleven case reports for
anaphylaxis with no deaths.
• Adherence between SLIT and SCIT (Bender 2015)
– Three large pharmacy refill databases showed
• 53% of SCIT patients being non-adherent after year one and
84% being non-adherent by the third year of treatment.

• 56.3% of SLIT patients were non-adherent after year one and
86.6% were non-adherent by the third year.
• Cost effectiveness between SLIT and SCIT (Dranitsaris et al.
2014)
– Monthly drug cost in double-blind placebo controlled RCTs
• Oralair $1,003 1st year, 2nd and 3rd $1,983.84.

• Grazax $2,171 1st year, 2nd and 3rd $4,327.
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• SCIT seasonal $1,951

year,

2nd

and

3rd

$3,867.

• Obstacles to immunotherapy: out-of-pocket costs, use of OTC
drugs, and adherence to long term therapy.
• Education about the therapy options and potential for cost savings
long term.

• As a provider, know when to refer and not to refer to an allergist.
– Know what your patient wants long term
– Know if long term therapy is feasible from a financial stand
point.
• For those with severe AR perform RAST (IgE antibodies) or skin
prick test (antigen introduced) to determine triggers and need for
immunotherapy.
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– In one SCIT meta-analysis, 51 RCTs were examined totaling
2,871 patients. It was found that there was a clinically
significant reduction in symptomatic score with -0.73 SMD and
medication score with -0.57 SMD (Aboshady et al. 2014)
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